Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 6, 2010
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practiceNicole M Agostino, Vernon M Chinchilli, Christopher J Lynch, et al.
Journal of the American Academy of Dermatology|April 17, 2007
Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapiesGregory J Fulchiero, Heather Salvaggio, Joseph J Drabick, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 28, 2020
Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysisCongzhou M Sha, Eric J Lehrer, Clara Hwang, et al.
Cancer Biology & Therapy|August 31, 2017
Identification of WEE1 as a target to make AKT inhibition more effective in melanomaOmer F Kuzu, Raghavendra Gowda, Arati Sharma, et al.
Cancer Letters|July 15, 2017
Improving pharmacological targeting of AKT in melanomaOmer F Kuzu, Raghavendra Gowda, Arati Sharma, et al.
Oncotarget|April 24, 2018
ATM/RB1 mutations predict shorter overall survival in urothelial cancerMing Yin, Petros Grivas, Hamid Emamekhoo, et al.
Journal of Medical Genetics|January 23, 2016
An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignanciesMaria J Baker, Alisa M Goldstein, Patricia L Gordon, et al.
Cancer Biology & Therapy|February 19, 2015
Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expressionJacob S Lipkin, Syed M Rizvi, Zoran Gatalica, et al.
Pageof 6